$107.21 +0.51 (%) Johnson & Johnson - NYSE

Nov. 26, 2014 | 04:00 PM

Partner Headlines

  1. U.S. Stocks Attractive As Euro-Area Economy Slides

    GuruFocus | Nov. 26, 2014 | 12:27PM EST
  2. Consolidated Edison Has Increased Dividends for 40 Years

    GuruFocus | Nov. 25, 2014 | 10:53AM EST
  3. Walmart Still Rules The Retail Roost

    GuruFocus | Nov. 21, 2014 | 13:05PM EST
  4. Riding The Bull Market With These 2 Momentum ETFs

    Benzinga | Nov. 20, 2014 | 15:10PM EST
  5. Inflation Low? Not If You’re Investing For Long Haul

    YCharts | Nov. 20, 2014 | 09:59AM EST
  6. Mallinckrodt tops, no outlook

    IBD | Nov. 19, 2014 | 19:01PM EST
  7. Making Money With Charles Payne: 11/19/14

    FoxBusiness | Nov. 19, 2014 | 18:00PM EST
  8. Mallinckrodt Q4 Earnings Beat Views, But Outlook Hazy

    IBD | Nov. 19, 2014 | 17:35PM EST
  9. Mallinckrodt Earnings Beat But No New Guidance

    IBD | Nov. 19, 2014 | 11:42AM EST
  10. Incyte Building Blockbuster Drug One Disease At A Time

    IBD | Nov. 17, 2014 | 15:58PM EST
  11. Guru Ken Fisher's Top Five Quarterly Stocks

    GuruFocus | Nov. 16, 2014 | 23:17PM EST
  12. ADHD drug hits FDA trouble

    IBD | Nov. 13, 2014 | 18:37PM EST
  13. Mallinckrodt ADHD Drug Hits FDA Trouble; Stock Drops

    IBD | Nov. 13, 2014 | 11:09AM EST
  14. What Johnson & Johnson's 'Chart Watchers' Need To Know

    Benzinga | Nov. 12, 2014 | 12:28PM EST
  15. Jim Cramer Weighs In On Johnson & Johnson And Toyota Motor

    Benzinga | Nov. 10, 2014 | 21:09PM EST
  16. Merck Down On Hepatitis C Data; Gilead Rises

    IBD | Nov. 10, 2014 | 11:14AM EST
  17. #PreMarket Primer: Monday, November 10: Nuclear Talks Enter Second Day

    Benzinga | Nov. 10, 2014 | 07:54AM EST
  18. Which Mega-Caps Aren't Paying Taxes?

    Benzinga | Nov. 5, 2014 | 09:04AM EST
  19. Dividend Growth Stocks With A Defined-Benefit Pension

    GuruFocus | Nov. 4, 2014 | 11:26AM EST
  20. Johnson & Johnson Fairly Valued - I Will Bet on It

    GuruFocus | Oct. 30, 2014 | 12:26PM EST
  21. Ebola Vaccine Contenders

    Benzinga | Oct. 30, 2014 | 10:44AM EST
  22. Video: Facebook, Gilead Post Earnings After The Close

    IBD | Oct. 28, 2014 | 14:00PM EST
  23. Receptos Soars After Lead Drug Racks Up Another Win

    IBD | Oct. 28, 2014 | 11:46AM EST
  24. Gilead Rises Ahead Of Q3 Earnings As Rivals Wobble

    IBD | Oct. 27, 2014 | 15:38PM EST
  25. Procter & Gamble Co Shares Lower Following Management Change

    Benzinga | Oct. 23, 2014 | 13:42PM EST
  26. 3M the Cash Generation Machine in the Industrials Segment

    GuruFocus | Oct. 23, 2014 | 12:53PM EST
  27. Ebola Test To Begin In Jan.

    IBD | Oct. 22, 2014 | 18:53PM EST
  28. Drug ETFs Attractive Buys On Pullback

    Benzinga | Oct. 22, 2014 | 17:10PM EST
  29. Major Indexes End Win Streak; Super Micro Surges

    IBD | Oct. 22, 2014 | 16:24PM EST
  30. Worried? Picks Of Mr. Cautious, 80% In Stocks

    YCharts | Oct. 22, 2014 | 15:51PM EST
  31. Stocks Erase Modest Gains; Apple Flirts With Breakout

    IBD | Oct. 22, 2014 | 15:06PM EST
  32. Dividend Aristocrats In Focus Part 24: Consolidated Edison

    GuruFocus | Oct. 22, 2014 | 14:43PM EST
  33. #PreMarket Primer: Wednesday, October 22: Johnson & Johnson Develops Ebola Vaccine

    Benzinga | Oct. 22, 2014 | 08:13AM EST
  34. Celgene Reports More Good Crohn's Disease Data

    IBD | Oct. 21, 2014 | 11:32AM EST
  35. Bill Frels Comments on Johnson & Johnson

    GuruFocus | Oct. 20, 2014 | 16:14PM EST
  36. Celgene's Crohn's Disease Drug Hits Its Marks

    IBD | Oct. 20, 2014 | 11:16AM EST
  37. What Have We Really Lost?

    GuruFocus | Oct. 20, 2014 | 10:10AM EST
  38. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga | Oct. 19, 2014 | 10:19AM EST
  39. Illumina Helps Make Gene Sequencing Affordable

    IBD | Oct. 17, 2014 | 18:48PM EST
  40. #PreMarket Primer: Thursday, October 16: This Year's Spending Season Could Be Muted

    Benzinga | Oct. 16, 2014 | 07:40AM EST
  41. The Key Drivers For Johnson & Johnson

    GuruFocus | Oct. 15, 2014 | 19:10PM EST
  42. Was Celgene's Crohn's Disease Drug Worth The Price?

    IBD | Oct. 15, 2014 | 17:39PM EST
  43. Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark'

    Benzinga | Oct. 15, 2014 | 16:42PM EST
  44. J&J raises outlook on Q3 beat

    IBD | Oct. 14, 2014 | 18:51PM EST
  45. Making Money With Charles Payne: 10/14/14

    FoxBusiness | Oct. 14, 2014 | 18:00PM EST
  46. Johnson & Johnson Conference Call Highlights

    Benzinga | Oct. 14, 2014 | 15:21PM EST
  47. Deutsche Bank Says Gilead Sciences Stock Reaction Is Overdone

    Benzinga | Oct. 14, 2014 | 13:59PM EST
  48. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD | Oct. 14, 2014 | 11:54AM EST
  49. Stocks Up, Whittle Early Gains; Skyworks Spikes On Guidance

    IBD | Oct. 14, 2014 | 10:42AM EST
  50. JPM Posts Mixed 3Q as Trading Rebounds

    FoxBusiness | Oct. 14, 2014 | 09:40AM EST
Trading Center